When do you think physicians should seriously consider prescribing PCSK9 inhibitors for the prevention of heart attack and stroke in people with ASCVD or diabetes, based on the results of the VESALIUS-CV trial?  

The VESALIUS-CV trial included individuals with atherosclerosis or diabetes, an LDL-c >90 mg/dl, but without a history of an MI or stroke on maximally tolerated statin therapy/ ezetimibe, and demonstrated a reduction in major adverse cardiovascular events. Overall, the study reaffirmed the value ...